Epygen Biotech

What Epygen Biotech does

Epygen Biotech is a Dubai-headquartered, founder-led biopharmaceutical company that researches and manufactures therapeutic proteins across oncology, cardiovascular, hormone, and vaccine indications, with its primary manufacturing operations at a cGMP-certified facility in Patalganga, Maharashtra, India, and a US business development office in New York. The company's technology base centers on recombinant protein expression in E. coli and CHO cells, high-cell-density fermentation, proprietary chromatographic separation, and precision refolding techniques, supplemented by a licensed hyper-productive C1 protein production platform from Dyadic International that underpins its SARS-CoV-2 vaccine candidate. Core products include Recombinant Streptokinase (thrombolytic), Pegfilgrastim and Filgrastim biosimilars (G-CSF for chemotherapy-induced neutropenia), Bevacizumab (anti-VEGF monoclonal antibody), and Teriparatide (recombinant PTH for osteoporosis).

Epygen generates revenue through three streams: direct sales of its own therapeutic protein portfolio to healthcare providers and the private market, government procurement (notably for its COVID-19 vaccine candidate targeted at less than Rs 150/dose), and contract development and manufacturing organization (CDMO) services for biopharma clients seeking end-to-end biologics production from clone to vial. The company's customer base spans government health authorities, healthcare providers, and biopharmaceutical clients, supported by partnerships with CSIR-IMTECH, IIT Bombay, IIBR, VTT Finland, and Dyadic International. Its Patalganga facility carries CDSCO cGMP, RCGM, and DSIR approvals, with 24 million vials/year fill-finish capacity and fermentation scale-up to 150L, positioning it as a regional player focused on affordable biologics for South Asia and adjacent markets.

Name

Epygen Biotech

Legal name

Epygen Biotech

Website

https://epygenbiotech.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Epygen Biotech is a Dubai-headquartered biopharmaceutical company that develops and manufactures affordable recombinant therapeutic proteins and biosimilars for oncology, cardiovascular, hormones, and vaccines, serving healthcare providers, government health authorities, and biopharma CDMO clients from its cGMP facility in India.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industries

Oncology Biosimilars (HLAAAHAG), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Therapeutic proteins
• Biopharmaceutical manufacturing
• Biosimilar development
• Contract development manufacturing
• Recombinant protein expression

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Services: Contract Development and Manufacturing Organization offering end-to-end biological services from clone development to vialing for intracellular/extracellular therapeutic proteins. Services include R&D, analytical development, scale-up, manufacturing, fill-finish, and regulatory support.
2. Therapeutic Protein Manufacturing: Manufacturing and sale of therapeutic proteins including biosimilars for Oncology, Cardiovascular, and Vaccines. Products include recombinant Streptokinase, Filgrastim, Pegfilgrastim, Bevacizumab, and Teriparatide.
3. Vaccine Development and Production: COVID-19 vaccine development using C1 platform targeting RBD variants. Planning to produce 100 million doses initially.

Pricing tiers

Distribution channels3 records

Marketing channels4 records

Core offering

Epygen Biotech is a biopharmaceutical company that researches, develops, and manufactures recombinant therapeutic proteins (biosimilars and biologics) for oncology, cardiovascular, hormone disorders, and vaccines, and provides end-to-end Contract Development and Manufacturing Organization (CDMO) services for therapeutic proteins and vaccines. Its portfolio includes Recombinant Streptokinase, Pegfilgrastim, Bevacizumab, Filgrastim, Teriparatide, and a SARS-CoV-2 vaccine candidate produced at a cGMP facility near Mumbai.

Product overview

Epygen Biotech is a biopharmaceutical company offering a portfolio of therapeutic proteins and biologics for oncology, cardiovascular, hormones, and vaccines, supplemented by CDMO (Contract Development and Manufacturing Organization) services. Core products include Recombinant Streptokinase (cardiovascular thrombolytic), Pegfilgrastim and Filgrastim (G-CSF for oncology neutropenia), Bevacizumab (anti-VEGF monoclonal antibody for oncology), Teriparatide (PTH for osteoporosis), and SARS-CoV-2 vaccine candidate. The CDMO division provides end-to-end manufacturing services for biologics and vaccines using microbial expression platforms with capacity up to 150L fermentation scale.

Differentiator

Problem solved

Functional benefit

Brands

• Epygen Cares Foundation: Corporate Social Responsibility (CSR) division of the Epygen group operating on 'Not for profit' basis, engaging in human and social welfare activities including health awareness, education, and environmental initiatives.

Products and services

• Recombinant Streptokinase Recombinant thrombolytic protein (47 kDa, 414 amino acids) produced in E. coli for treatment of blood clots, used in cardiovascular applications including ST-elevated myocardial infarction (STEMI).
• Pegfilgrastim Pegylated form of filgrastim (G-CSF) with extended half-life (15-80 hours) for single-dose administration in chemotherapy-induced neutropenia and stem cell mobilization.
• Bevacizumab Recombinant humanized monoclonal IgG1 antibody (150 kDa) targeting vascular endothelial growth factor (VEGF) for tumor angiogenesis inhibition in oncology.
• Teriparatide Recombinant human parathyroid hormone (PTH 1-34), non-glycosylated 34-amino acid protein derived from E. coli for osteoporosis treatment by stimulating osteoblast activity.
• SARS-CoV-2 Vaccine COVID-19 vaccine candidate utilizing Dyadic's C1 protein production platform for expression of receptor-binding domain (RBD) antigens against SARS-CoV-2 variants, developed with funding from the Department of Biotechnology, Government of India.
• Filgrastim (Recombinant G-CSF) Recombinant 175-amino acid non-glycosylated protein (18.8 kDa) produced in E. coli using high-density fermentation for chemotherapy-induced neutropenia and stem cell mobilization.
• CDMO Services Contract Development and Manufacturing Organization services offering end-to-end biological manufacturing from clone development to vialing, including upstream processing, downstream purification, fill-finish, and analytical development for therapeutic proteins and vaccines.

Quantifiable outcome

• 24 million vials/year injectable fill-finish capacity
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• Dyadic InternationalcoreOEM/ Whitelabel/ Licensing PartnerEpygen licensed the C1-cell protein production platform from Dyadic International (NASDAQ: DYAI) to develop hyper-productive C1 SARS-CoV-2 RBD cell lines. The platform was developed together with Israeli Institute of Biological Research (IIBR) and VTT (Finland). The C1 platform enables ultra-high protein expression for low-cost vaccine and therapeutic protein production.
• CSIR IMTECHcoreStrategic or Co-development PartnerCollaborative project with Council of Scientific & Industrial Research IMTECH for development and scaling up of Recombinant Streptokinase production. MOU signed for research programs and technologies for novel biological molecules from cloning to scaling up.
• Indian Institute of Technology, BombaycoreStrategic or Co-development PartnerMOU signed for Corporate Affiliate Programme (CAP) at the Wadhwani Research Centre for Bioengineering (WRCB), Department of Chemical Engineering, IIT Bombay.
• Israeli Institute of Biological Research (IIBR)coreTechnology or IntegrationCollaborated with IIBR (Israeli government biotech lab) and VTT Finland to develop the C1 SARS-CoV-2 RBD cell line used in Epygen's COVID-19 vaccine development.
• VTT Technical Research Centre of FinlandcoreTechnology or IntegrationCollaborated with VTT (government-owned lab in Finland) and IIBR to develop the C1 SARS-CoV-2 RBD cell line for Epygen's COVID-19 vaccine using Dyadic's C1 platform.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Biocon: India's largest publicly listed biosimilars and biologics company with a directly overlapping oncology, cardiovascular and vaccines pipeline (bevacizumab, pegfilgrastim, trastuzumab). Comparable target market, technology base and biosimilars strategy to Epygen.
• Panacea Biotec: Indian vaccines and biosimilars manufacturer with overlapping pipeline in oncology G-CSF, oncology biologics and recombinant therapeutics. Highly comparable business model in India-domestic biologics.
• Reliance Life Sciences: Indian biopharmaceutical firm developing biosimilars (bevacizumab, rituximab, filgrastim) and recombinant therapeutics with a similar innovation-led approach to recombinant protein manufacturing in India.
• Syngene International: Indian contract development and biologics manufacturing organization providing end-to-end clinical and commercial biologics manufacturing similar to Epygen's CDMO offering, with overlapping client base of biopharma companies outsourcing manufacturing.
• Intas Pharmaceuticals: Indian biosimilars and biopharmaceutical player with a comparable oncology and immunology biosimilars basket (pegfilgrastim, filgrastim, bevacizumab) and CDMO-style manufacturing scale. Closely matched product overlap with Epygen.
• Biological E. Limited: Indian vaccines and biologics manufacturer with an active biosimilars pipeline and recombinant protein manufacturing capability. Overlaps with Epygen in vaccines and therapeutic protein production.
• Gennova Biopharmaceuticals: India-based biotech that develops and manufactures biosimilars, vaccines and recombinant therapeutics with a comparable headcount scale and therapeutic protein focus overlapping Epygen's oncology and immunology pipeline.

Broad incumbents

• Dr. Reddy's Laboratories: Large Indian pharmaceutical company with a global biosimilars portfolio including rituximab, pegfilgrastim and teriparatide. Larger and more diversified than Epygen but tackles the same therapeutic protein categories.
• Serum Institute of India: World's largest vaccine manufacturer; provides a relevant benchmark for recombinant protein and RBD-based vaccine manufacturing at scale using low-cost platforms and serves emerging markets comparable to Epygen's positioning.
• Zydus Cadila (Zydus Lifesciences): Large Indian pharmaceutical group with a biosimilars portfolio including oncology and cardiovascular recombinant therapeutics. Wide product breadth but overlaps with Epygen's core biosimilars strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EpygenBiotech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epygen Biotech